Moolenaar, Krishnamoorthi, Dunn Recommend Strengthened Controles to Prohibit the PLA from Accessing U.S. Clinical Trial Data

WASHINGTON DC — Chairman John Moolenaar (R-MI), Ranking Member Raja Krishnamoorthi (D-IL), and Rep. Neal Dunn (R-FL) of the House Select Committee on the Chinese Communist Party wrote to Secretary of Commerce Gina Raimondo, urging the Department to update its regulations to require a license prior to engaging with a Chinese military hospital for clinical trials.

In the summer of 2024, lawmakers sought information from the FDA regarding clinical trials conducted at Chinese military hospitals, FDA site visits in the People’s Republic of China, and clinical trials occurring in Xinjiang, where the CCP is committing a genocide against the Uyghur people.

As the Chinese Communist party seeks to potentially utilize biotechnology against the United States, the lawmakers write, “While the chemical compounds of drugs in development and related IP are not export controlled, [the Bureau of Industry and Security’s] proposed update to toughen military end-user and end-use controls could be strengthened to specifically state that cooperation with PLA medical institutions for the purpose of clinical trials is subject to a licensing requirement.”

They continue, “Specifically, we recommend updating the definition of “Military End User” to state medical infrastructure owned or operated by the national armed services of the PRC and other countries as appropriate constitutes a military end-use if a U.S. person is seeking to engage with the institution to conduct a clinical trial.”

View the lawmakers’ letter HERE